CVS Group (LON:CVSG) Announces Quarterly Earnings Results

Key Points

• CVS Group reported solid quarterly growth: Revenue rose 5.9% to £712.8 million, adjusted EBITDA increased 5.1% to £141.5 million, and adjusted EPS grew 6.9% to 85.6 pence.
• Like-for-like revenue growth was 2.1%, below the company’s 4%–8% target, as weak U.K. consumer confidence and hot weather reduced routine veterinary appointments. Management said trading has since normalized and expects results to meet market expectations.
• Financial flexibility and expansion remain priorities: CVS secured £350 million of refinancing through May 2030, is pursuing a £50 million share buyback, and continues investing in Australian and U.K. acquisitions while developing subscription and digital-growth initiatives.

CVS Group (LON:CVSG - Get Free Report) posted its quarterly earnings results on Thursday. The company reported GBX 85.60 earnings per share (EPS) for the quarter, Digital Look Earnings reports. CVS Group had a net margin of 2.31% and a return on equity of 5.35%.

Here are the key takeaways from CVS Group's conference call:

• Revenue rose 5.9% to £712.8 million and adjusted EBITDA increased 5.1% to £141.5 million, with the margin maintained at 19.9% despite inflationary pressures. Adjusted EPS grew 6.9% to 85.6 pence.
• Like-for-like revenue growth was 2.1%, below the company’s 4%–8% target, as weaker U.K. consumer confidence and unusually hot weather reduced routine appointments and delayed procedures. Management said trading has since returned to pre-heatwave levels and expects to perform in line with market expectations.
• CVS completed a refinancing that provides £350 million of committed facilities through May 2030 on improved terms, while leverage remained below its 2.0x threshold at 1.63x. The company is also progressing with a £50 million share buyback expected to finish within the next couple of months.
• Australia remains a key expansion opportunity, contributing about £20 million of EBITDA excluding central costs, with further Australian and U.K. acquisitions signed or completed since year-end. Management expects to invest around £50 million annually in acquisitions while remaining selective on valuation.
• Organic growth initiatives include the Healthy Pet Club Advanced subscription, which had attracted approximately 14,500 clients shortly after launch, alongside digital booking, CRM, AI consultation tools, and improved client communications. Capital expenditure is expected to moderate to about £30 million annually, potentially freeing cash for acquisitions or shareholder returns.

CVS Group Stock Down 5.6%

CVSG stock opened at GBX 1,228.55 on Thursday. The company has a debt-to-equity ratio of 92.34, a current ratio of 1.07 and a quick ratio of 0.90. The stock has a market capitalization of £835.05 million, a price-to-earnings ratio of 17.83, a PEG ratio of 1.77 and a beta of 1.07. The business's fifty day moving average price is GBX 1,289.88 and its two-hundred day moving average price is GBX 1,230. CVS Group has a fifty-two week low of GBX 1,062 and a fifty-two week high of GBX 1,648.

Wall Street Analysts Forecast Growth

CVSG has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a GBX 1,700 price objective on shares of CVS Group in a research note on Monday, July 27th. Berenberg Bank reiterated a "buy" rating and issued a GBX 2,000 target price on shares of CVS Group in a research note on Thursday. Jefferies Financial Group lifted their price target on CVS Group from GBX 1,350 to GBX 1,400 and gave the stock a "hold" rating in a report on Friday, July 31st. Finally, Shore Capital Group reissued a "hold" rating and set a GBX 1,400 price target on shares of CVS Group in a research report on Thursday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of GBX 1,666.67.

Insider Transactions at CVS Group

In other CVS Group news, insider Joanne Shaw bought 1,592 shares of CVS Group stock in a transaction dated Monday, August 10th. The stock was bought at an average price of GBX 1,287 per share, with a total value of £20,489.04. Also, insider Robin Alfonso purchased 768 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of GBX 1,294 per share, for a total transaction of £9,937.92. Over the last 90 days, insiders bought 3,860 shares of company stock valued at $4,956,696. 1.48% of the stock is currently owned by corporate insiders.

CVS Group Company Profile

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy. The Group operates from over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct"). The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.